Dapagliflozin: Clinical Practice Compared With Trial Data
Dapagliflozin: Clinical Practice Compared With Trial Data
The real-world data presented here may have greater generalisability to clinical practice, than data from clinical trials as patients with multiple co-morbidities or on multiple oral antidiabetic agents were included in the population analysed and are usually excluded from clinical trials. This study looked at a population of patients with diabetes referred for specialist management in secondary care and therefore may not be applicable to all patients in the primary care setting.
These data confirm that dapagliflozin is effective for use in clinical practice but clinicians should account for a higher level of intolerance to the side effects of dapagliflozin in clinical practice than that which is reported in clinical trials. In those who tolerated dapagliflozin, the commonly clustered metabolic risk factors of poor glycaemic control, obesity, and hypertension were all significantly improved. There was also a reduction in the use of other oral antidiabetic agents and insulin in this population.
Conclusions
The real-world data presented here may have greater generalisability to clinical practice, than data from clinical trials as patients with multiple co-morbidities or on multiple oral antidiabetic agents were included in the population analysed and are usually excluded from clinical trials. This study looked at a population of patients with diabetes referred for specialist management in secondary care and therefore may not be applicable to all patients in the primary care setting.
These data confirm that dapagliflozin is effective for use in clinical practice but clinicians should account for a higher level of intolerance to the side effects of dapagliflozin in clinical practice than that which is reported in clinical trials. In those who tolerated dapagliflozin, the commonly clustered metabolic risk factors of poor glycaemic control, obesity, and hypertension were all significantly improved. There was also a reduction in the use of other oral antidiabetic agents and insulin in this population.
Source...